Photo: BENOIT TESSIER / Reuters
Testing drugs for hepatitis C called daclatasvir and sofosbuvir showed that they help in the treatment of coronavirus. It is reported TASS with reference to the study of the Brazilian research Association name of Oswaldo Cruz (Fiocruz).
It is noted that the use of antivirals at an early stage can improve the clinical picture of patients and to reduce the number of severe cases.
According to experts, the daclatasvir and sofoluwe managed to prevent the propagation of infection in the three types of cells, including the cells of the lungs. Scientists also said that protective in infected cells the production of substances that cause inflammation, slows down.
In the study, daclatasvir showed higher efficiency compared with sofosbuvir, said the experts. In addition, both drugs showed better results in contrast to the antiviral drug broad spectrum of action of ribavirin and antiretroviral atazanavir.
Earlier, the head of the Russian direct investment Fund (RDIF) Kirill Dmitriev said on air of the TV channel “Russia 24” that the two Russian pharmaceutical company “R-Pharm” and “Promomed” — completed clinical trials of drugs from the coronavirus on the basis of favipiravir.
In April, the national Institute of Allergy and infectious diseases of the United States conducted a test of the drug against Ebola, called ramdevpir. It turned out that it helps in the treatment of coronavirus. According to the researchers, the drug reduces the duration of symptoms from 15 days to 11. Nevertheless, experts warned that ramdevpir will not be a “magic bullet” against the virus.
Video, photo All from Russia.